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Identity 




The NCBI RefSeq (Aug-2011) consensus sequence for 
AAMP differs at the 5-prime end from the manually 
sequenced version published initially. A diagram of the 
NCBI ReqfSeq (Aug-2011) version for rAAMP is 
shown here. 
Description 
The AAMP gene (NCBI RefSeq, Aug-2011) 
encompasses 6042 bp; 11 exons. 
Transcription 
1859 bp mRNA (NCBI RefSeq, Aug-2011). 
Pseudogene 
None are known. 
 
rAAMP encoding a 434 aa protein in normal cells.  The codon for AAMP's initiating methionine, the stop codon, and the poly-
adenylation sites are indicated at 85-87, 1387-1389, and 1774-1779, respectively. Untranslated sequence is indicated in the hatched 
regions at the 3' end of exon 1 and the 5' end of exon 11. The poly-adenosine tail, 1793-1859, is included. 
 
The bulk of AAMP's sequence  is constituted by WD40 domains that are known to commonly fold to form a platform for active portions 
of a protein. Thus the stretch of contiguous glutamic acid residues should be available for interactions with other proteins. Also, binding of 
other proteins may occur to regions of these repeats. The WD40 repeats are known to mediate aggregation of subunits to form complex, 
multi-protein structures. Two immunoglobulin-type domains are designated by pairs of cysteines, (C96 - C130) and (C216 - C265). AAMP 
may play a negative role in Nod2-mediated NF-kB activation via a physical interaction in the region indicated. A physical interaction 
between AAMP and thromboxane A2 receptors (TPalpha and TPbeta) has been suggested to occur via multiple sites with no particular 
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Protein 
Note 
The NCBI RefSeq (Aug-2011) consensus sequence for 
AAMP (434 aa) is shorter than initially reported (452 
aa, 52 kDa). 
Description 
434 amino acids, 49 kDa protein (NCBI RefSeq, Aug-
2011). 
Expression 
AAMP is widely expressed among many types of 
mammalian cells and has been conserved in evolution. 
Localisation 
AAMP was initially detected in the cytoplasm of many 
types of nucleated mammalian cells and was strongly 
expressed in endothelial cells, cytotrophoblasts, and
poorly differentiated colon adenocarcinoma cells in 
lymphatics. AAMP has been observed at the luminal 
edges of endometrial cells and has been found in the 
extracellular environment of vascular-associated 
mesenchymal cells. 
Function 
Functional studies and associations suggest roles fr 
AAMP in angiogenesis, including endothelial tube 
formation, migration of endothelial and smooth muscle 
cells, neointima formation, and thromboxane A 
receptor interactions. In immune cells AAMP may be 
involved in the regulation of NF-kappaB activation 
mediated by Nod2. The common occurrence of WD40 
domains in signaling proteins supports a signaling 
function as a possibility for AAMP. The epitope, 
ESESES, that AAMP shares with alpha-actinin and a 
smaller protein specific for fast skeletal muscle, 
suggests that it may have cytoskeletal interactions. 
Although AAMP was described as having heparin-
binding capacity in melanoma cells, the NCBI RefSeq 
(Aug-2011) version of AAMP does not include the 
heparin-binding sequence (encodes RRLRR) in the  
coding sequence. The RefSeq version of AAMP 
identifies the initiating methionine (85-87) as being 3' 
to the sequence encoding RRLRR (70-84). 
Homology 
AAMP shares homology with the other members of the 
WD40 repeat superfamily. Several of the WD40 repeat 
proteins also contain an amino terminal run of glutamic 
acid residues outside of their WD repeats. The two 
immunoglobulin-type domains in AAMP resemble 
those of the immunoglobulin superfamily members, 
including domains of NCAM, DCC, NgCAM, etc. 
Mutations 
Note 
AAMP was initially cloned and sequenced as a 
transcript for a 452 aa, 52 kDa protein. It was obtained 
from an expression library derived from melanoma 
cells of a brain metastasis. However the amino 
terminus was missing from the library clone. AAMP's 
amino terminus was determined by 5' RACE from 
human brain mRNA. Two versions were obtained and 
both differed from the NCBI RefSeq (Aug-2011) 
version of AAMP. The one shown contains coding 
sequence upstream from the initiating methionine in the 
RefSeq version. This alternative form may represent a 
fusion protein due to an in-frame insertion or a 
chromosomal rearrangement. AAMP potentially gains 
heparin binding functionality when sequence upstream 
from AUG at nucleotides 85-87 is preceded by an 
alternative initiating methionine codon that enables 
translation of the codons for RRLRR. 
Germinal 
None are known. 
Somatic 
Chromosomal rearrangements or insertions that place 
an initiating methionine codon further upstream than 
the methionine at 85-87 permit AAMP to gain heparin 
binding function when nucleotides 70-84 are translated. 
 
rAAMP encoding a 452 aa protein (alternative form).  An alternative AUG was detected when the amino terminus was manually 
sequenced with 5' RACE using brain mRNA. It is shown in red. Its upstream location permits 17 codons to encode amino acids, including 
5 codons for RRLRR, a heparin-binding site. Sequences of the alternative forms described for AAMP are the same as the NCBI RefSeq 
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Implicated in 
Gastrointestinal stromal tumor (GIST) 
Note 
GISTs are the most common mesenchymal tumors of 
the digestive tract and are believed to arise from the 
interstitial cells of Cajal. They respond to imitanib, a 
tyrosine kinase inhibitor, which is also used to trea  
myeloid leukemia. Expression of AAMP was found to 
be increased in GISTs with mutated KIT. Expression of 
AAMP among various soft tissue sarcomas and normal 
tissues was highest in the GISTs. AAMP ranks high 
among the upregulated genes in GISTs. 
Myeloid leukemia (chronic (CML) and 
acute (AML) forms) 
Note 
AAMP is expressed in myeloid leukemia cell lines and 
its expression is repressed by imitanib (mainline 
treatment drug for chronic myeloid leukemia), 
deferasirox (iron chelator that decreases cell 
proliferation), and anisomycin, an inducer of apoptosis. 
Lymphoma (B and T cell origins, non-
Hodgkins and Hodgkins types) 
Note 
AAMP is expressed in activated T lymphocytes, 
monocytes, and lymphoma cells. Compared to normal 
B cells, AAMP is increased in non-Hodgkins 
lymphomas and in classical Hodgkins lymphoma. 
Melanoma (melanocyte origin, usually 
skin) 
Note 
In lysates of a melanoma cell line obtained from a brain 
metastasis, the size of the protein that reacted with anti-
AAMP was 52 kDa, thus corresponding to the size 
predicted by an alternative transcript. The alternative 
version of AAMP could have resulted from a 
chromosomal rearrangement due to 2q35 breakage in 
the amino terminal region of AAMP. Placement of 
AUG at the 5' end of nucleotide 34 to serve as an 
alternative initiating methionine codon permits 
expression of the heparin binding site, RRLRR 
(nucleotides 70-84 in the NCBI ReqSeq (Aug-2011) 
version of AAMP) as a gain of function. 
Breast cancer (ductal cell origin most 
common) 
Note 
Expression profiling of human breast cancer cells 
versus mammary epithelial cells revealed higher 
expression of AAMP in the tumor cells. AAMP 
expression is higher in ductal carcinoma in situ (DCIS) 
with necrosis compared to DCIS without necrosis. 
However, expression profiling of DCIS and invasive  
 
ductal carcinoma (IDC) paired specimens from the 
same patients revealed decreased AAMP in IDC. 
AAMP expression may be relevant for the development 
of DCIS. 
Glial brain tumors (neuroectodermal cell 
origin) 
Note 
When compared with normal, glioblastomas (Grade IV 
astrocytomas) and oligodendrogliomas (Grades II - III) 
demonstrated slightly elevated levels of AAMP 
expression. Expression of AAMP was increased in drug 
resistant glioblastomas, primary and recurrent. 
Colon neoplasia (benign adenomas and 
carcinoma arise from glandular cells of 
the mucosa in the gastrointestinal tract) 
Note 
Expression profiling of normal mucosa and colorectal 
adenomas from the same patients showed that AAMP 
was slightly increased in the adenomas. However, a 
small dataset of colon tubular adenomas harboring 
focal adenocarcinomas, with microdissections of paired 
samples from each, showed that AAMP may become 
decreased in the incipient carcinomas. Although 
AAMP may play a role in the development of colonic 
neoplasia, it has not been shown to be positively 
involved in progression of adenomas to malignancy. 
Epidermoid carcinoma (keratinocyte 
origin if arises in skin) 
Note 
AAMP is expressed in squamous carcinoma cell lines. 
In one cell line studied with PTEN knocked down, the
expression of AAMP also fell significantly. Also, for 
tumors from a radiosensitive cell line, AAMP 
expression fell significantly in radioresistant tumors 
derived from the sensitive cell line. 
Cervical cancer (usually arises from 
squamous type cells) 
Note 
In a study of cervical carcinoma HeLa cells treated 
with epidermal growth factor in a time course, 
expression of AAMP was increased at 2-8 hours. 
Ovarian cancer (often arises from 
serous cells) 
Note 
Cancer cells prepared from primary cultures of ovarian 
papillary serous adenocarcinomas revealed increased 
AAMP expression in 2 of 3 carboplatin resistant tumors 
whereas none of the tumors from 3 patients with 
sensitivity to carboplatin demonstrated comparable 
levels. 
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Papillary thyroid carcinoma (arises from 
cells in thyroid follicles) 
Note 
Analysis of papillary thyroid carcinoma tumors 
matched with normal thyroid from nine patients found 
that AAMP expression fell slightly in the tumors. 
Pulmonary carcinoma (multiple types of 
cells can be the origin) 
Note 
AAMP's expression in a lung alveolar adenocarcinoma 
cell line was down-regulated by TGF-beta that was 
added to induce an epithelial-mesenchymal transition. 
Chromosomal rearrangements at 2q35 
Note 
The location of AAMP at 2q35 imparts susceptibility to 
chromosomal rearrangements involving the terminal 
region of chromosome 2's long arm, q. Terminal 
regions are more susceptible to rearrangements than the 
midregions of chromosomes. Fusion transcripts and 
proteins result from breakage and rearrangements tha  
occur in unstable genomes. Several fusion proteins 
resulting from rearrangements involving other genes i  
this region have been reported in association with 
malignancy. Rearrangements that place in-frame 
coding sequence upstream from nucleotides 70-84 in 
the NCBI ReqSeq (Aug-2011) version of AAMP 
permit a gain of function, i.e. heparin-binding, to occur. 
Breakpoints 
Note 
Clones obtained in 5' RACE studies of AAMP's amino 
terminus revealed a breakpoint between nucleotides 30 
and 31 with inclusion of upstream sequence that did not 
match the NCBI RefSeq (Aug-2011) form of AAMP 
and also another version with a breakpoint between 
nucleotides 33 and 34 and introduction of an alternative 
AUG. A schematic of the latter alternative form was 
shown earlier. The location of AAMP at 2q35 places it 
in a region near the end region of the chromosomal arm 
where breakpoints are more likely compared to the 
centromeric region. Importantly, in the sequences of 
the consensus and variant forms, in-frame codons are 
present for a heparin binding region that can be 
translated if an alternative initiating methionine is 
introduced upstream. 
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